CureMetrix vs TeraRecon

TeraRecon's AI Framework is, in the vendor's words, a vendor-agnostic hosting platform for clinical AI algorithms, while CureMetrix sells mammography software of its own, cmAngio and cmTriage. cmAngio quantifies breast arterial calcification (V1.0, K232367, decided October 5, 2023). Applied Radiology reports that a later clearance (K250754, decided April 10, 2025) expanded it to GE platforms, and ITN reports validation on Hologic first.

TeraRecon is based in Fremont, California, and says it serves over 2,000 hospitals. Its DETECT product runs imaging biomarkers during CT review through plaque, hepatic and spine analysis modules, and it supports "FDA-cleared biomarkers" without naming them. A cloud SaaS transformation was announced on December 2, 2024. A women's imaging center is the CureMetrix customer. A hospital with a cardiac CT program that also reads screening mammograms could run both.